Faeth Therapeutics (FTH) Liabilities and Shareholders Equity (2020 - 2026)

Faeth Therapeutics (FTH) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $145.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $145.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.7 million (up 43.71% YoY) and the FY2025 annual result came in at $22.9 million, down 49.51% from the prior year.
• Liabilities and Shareholders Equity rose to $145.4 million in Q1 2026, from $22.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $150.0 million in Q1 2022 to a low of $22.9 million in Q4 2025.
• A 5-year average of $83.8 million and a median of $78.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 14.01% — and 2025, when it plunged 49.51%.
• Tracing FTH's Liabilities and Shareholders Equity over 5 years: stood at $118.4 million in 2022, then tumbled by 37.17% to $74.4 million in 2023, then plunged by 39.01% to $45.4 million in 2024, then sank by 49.51% to $22.9 million in 2025, then soared by 534.81% to $145.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $145.4 million (Q1 2026), $22.9 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.